🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Vaccine hopes, global M&A boost European stocks

Published 14/09/2020, 08:26
© Reuters.
FCHI
-
DE40
-
GILD
-
NVDA
-
AZN
-
IMMU
-
STOXX
-
9984
-
SX8P
-

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)
Sept 14 (Reuters) - European stocks kicked off the week on a
positive note, as hopes of a coronavirus vaccine and a flurry of
global M&A activity overshadowed worries about a disorderly
Brexit.
The pan-European STOXX 600 index .STOXX rose 0.7% by 0711
GMT on Monday, hitting its highest level in over a week, while
the German .GDAXI and French .FCHI indexes clocked similar
gains.
News over the weekend that AstraZeneca AZN.L had resumed
clinical trials of its COVID-19 vaccine after being suspended
last week sparked a wave of buying across global stocks. The
British drugmaker's shares AZN.L rose 0.5%. Meanwhile, U.S. chipmaker Nvidia Corp NVDA.O said it would
buy UK-based chip designer Arm from Japan's SoftBank Group
9984.T for as much as $40 billion in a deal set to reshape the
global semiconductor landscape, spurring a 1% gain in Europe's
tech sector .SX8P . Frankfurt-listed shares of Immunomedics IMMU.O IMMU.F
shot up 109.7% on news Gilead Sciences GILD.O will acquire the
U.S. biopharmaceutical company for $21 billion. However, adding to fears of a messy departure for Britain
from the European Union, car industries from both sides warned
that failure to secure a free trade agreement would cost the
sector 110 billion euros ($130 billion) in lost trade over the
next five years.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.